Hi JR Ewing. Welcome to the spotlight and don't sell

New Post Public Reply Private Reply Replies (1) Message Board
Respert24 JR Ewing #116807
766
Hi JR Ewing. Welcome to the spotlight and don't sell yourself short. You may very well become one of the best posters here. Back when I first started posting regularly I certainly didn't think I'd be awarded both 2020 & 2021 poster of the year, but here we are. The people have spoken, and they chose wisely if I’m being honest. But enough about me.

Let's answer your questions.

If Leronlimab wasn't a viable candidate for the various conditions it's in trials for the FDA wouldn't have approved those trials, and certainly wouldn't have approved follow up trials which are based on those initial trials showing signals of success. Many a drug is willingly pulled from drug trials because efficacy is non-existent or the safety issues overwhelm whatever possible efficacy exists. Notwithstanding Aduhelm and Remdesivir, the cream typically rises to the top and the chaff gets separated from the wheat well before anyone is allowed to make a pancake.

(Bonus points to anyone who knows the kids book that wheat/pancake comment derives from)

Another strong signal that Cytodyn has something in LL is just how dedicated the bashers are in their efforts to discredit and derail the success of Leronlimab. Nobody wastes that much time, effort, and money, on something that isn't worth it. It's been happening on every possible message board, relentlessly, for years now. And that's not even talking about the dbags working the same program from their "media" or "investor" companies like STAT.

To your second question, if the SEC was after Cytodyn and/or Nader we'd have heard about it. Though I’m no expert on the matter. I do think we wouldn’t have seen everyone stick around, especially the expert in SEC regulations who took on the chairman of the board role, had there been some major malfeasance on the part of Nader and/or the board. And especially if there wasn’t any promise in Leronlimab’s ability to perform. If it were a toxic environment, or the drug didn’t work, or there were some seriously illegal things going on the board would know and people would be fleeing en masse.

Now we’ll just need a follow up post to know which supercar you’ll buy once Cytodyn hits its first dinger, and whether you’re on Team Pie or Team Cake.

- Daytime Respert

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Growth Outlook for the Packaging Robots Market to 2032

Updated Category News Views 128

The Expanding Landscape of Packaging Robots The Packaging Robots Market is on an exciting trajectory, projected to soar from an estimated USD 6.02 billion in 2023 to an impressive USD 16.67 billion by 2032. This remarkable growth is fueled by continuous technological advancements and the ever-increasing demand for automation, as businesses strive for greater efficiency in...

Continue Reading
Analyzing the Short Interest Trends for AutoZone Inc

Updated Category News Views 88

Understanding AutoZone Inc's Short Interest AutoZone Inc (NYSE: AZO) has recently seen a noteworthy rise in its short interest, which now stands at approximately 5.91% higher than its previous report. This increase translates to around 317 thousand shares being sold short, representing 2.15% of the total regular shares available for trading. Given its trading patterns, it...

Continue Reading
Join the Fight: Investors Urged to Act Against Flywire's Missteps

Updated Category News Views 180

Critical Insights into Flywire Corporation's Recent Challenges In light of recent events, investors in Flywire Corporation (NASDAQ: FLYW) are presented with a pivotal opportunity to address potential securities fraud claims. Allegations suggest that the company might have communicated misleading business information to the public, raising concerns among its shareholders....

Continue Reading
LEPAS L8: A Game-Changer for Electric Vehicle Enthusiasts

Updated Category News Views 308

LEPAS L8: Redefining the Future of NEVs The innovative leap forward in the world of electric vehicles comes with Chery Group's brand new energy vehicle (NEV) brand, LEPAS, and its latest offering, the L8 model. The introduction of the L8 marks a significant milestone for Chery as it establishes a new standard in driving sophistication. This model is poised to make waves...

Continue Reading
Integra LifeSciences Launches Pediatric Registry for AERA System

Updated Category News Views 128

Integra LifeSciences Initiates Pediatric AERA Registry Integra LifeSciences Holding Corporation (Nasdaq: IART), a premier global leader in medical technology, has taken a significant step forward by enrolling the first patient in the Acclarent AERA Pediatric Registry. This multi-center observational registry aims to evaluate the real-world applications of the AERA...

Continue Reading